<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01310036</url>
  </required_header>
  <id_info>
    <org_study_id>ML25637</org_study_id>
    <nct_id>NCT01310036</nct_id>
  </id_info>
  <brief_title>A Study of Tarceva (Erlotinib) as First Line Therapy in Patients With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations</brief_title>
  <official_title>An Open-label Multi-center Study of Erlotinib (TarcevaÂ®) as First Line Therapy Until and Beyond Disease Progression in NSCLC Patients Who Harbour EGFR Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label, single arm study will evaluate the safety and efficacy of Tarceva
      (erlotinib) as first-line therapy in patients with stage IV or recurrent non-small cell lung
      cancer who harbour epidermal growth factor receptor (EGFR) mutations. All patients will
      receive Tarceva 150 mg daily orally until disease progression or unacceptable toxicity
      occurs. At the investigator's discretion, patients may receive Tarceva beyond disease
      progression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2011</start_date>
  <completion_date type="Actual">December 30, 2016</completion_date>
  <primary_completion_date type="Actual">December 30, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival by RECIST (PFS1), defined as time from first dose until documented RECIST disease progression or death of any cause at any time, whichever occurs first</measure>
    <time_frame>42 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival by investigator's discretion (PFS2), defined as time from first study dose to off-Tarceva PD assessed by investigator based on overall clinical evaluation not limited to RECIST</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (all patients and patients with EGFR mutation E19del or L858R)</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (all patients and patients with EGFR mutation E19del or L858R)</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (patients with EGFR mutation E19del or L858R)</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (all patients and patients with EGFR mutation E19del or L858R)</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between EGFR mutations in plasma and clinical outcome (ORR/PFS/OS)</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Non-Squamous Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib [Tarceva]</intervention_name>
    <description>150 mg orally daily</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;/= 18 years of age

          -  Stage IV or recurrent non-small cell lung cancer (NSCLC)

          -  Presence of mutation(s) in exon 18 through exon 21 of epidermal growth factor receptor
             (EGFR), (except T790M single mutation only)

          -  Measurable disease (at least one lesion &gt;= 10 mm in longest diameter)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Adequate hematological, renal and liver function

        Exclusion Criteria:

          -  Patients with T790M single mutation only

          -  Prior exposure to agents directed at the human epidermal receptor (HER) axis, e.g.
             erlotinib, gefitinib, cetuximab, trastuzumab

          -  Prior chemotherapy or systemic anti-cancer therapy for advanced NSCLC disease

          -  Symptomatic or uncontrolled central nervous system (CNS) metastases

          -  Other malignancy within the last 5 years, except for carcinoma in situ of the cervix,
             or basal or squamous cell carcinoma of the skin, or surgically treated localized
             prostate cancer, or surgically treated ductal cell carcinoma in situ of the breast

          -  Any significant ophthalmologic abnormality

          -  Pre-existing parenchymal lung disease such as pulmonary fibrosis

          -  Use of coumarins (for anti-coagulation therapy the use of low molecular weight heparin
             is recommended instead)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Hospital; Oncology</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital; Clinical Oncology</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hosp; Dept. Of Clinical Onc</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gil Hospital. Gachon University</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center; Medical Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital; Medical Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital; Internal Medicine</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital; Dept of Internal Medicine</name>
      <address>
        <city>Kaohsiung</city>
        <zip>00833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans General Hospital; Internal Medicine</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital; Pulmonary and Critical Care Medicine</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital; Dept of Internal Medicine</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung Uni Hospital; Dept of Hematology and Oncology</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi-Mei Medical Centre; Hematology &amp; Oncology</name>
      <address>
        <city>Tainan</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan Uni Hospital; Internal Medicine</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation - Linkou; Chest Dept</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn Hospital; Medical Oncology</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pramongkutklao Hospital; Medicine - Medical Oncology Unit</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital; Department of Internal Medicine, Division of Respiratory</name>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2011</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 16, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>December 15, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

